One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: A retrospective claims database analysis

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Kim, Edward ^a   You, Min ^a   Pikalov, Andrei ^b   Van Tran, Quynh ^b   Jing, Yonghua ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; DATA BASE; DRUG EXPOSURE; FEMALE; FOLLOW UP; GENDER; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MENTAL HOSPITAL; MENTAL PATIENT; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; COMPARATIVE STUDY; DRUG COST; ECONOMICS; FACTUAL DATABASE; INSURANCE; LONGITUDINAL STUDY; MIDDLE AGED; PROPENSITY SCORE; STATISTICS;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COHORT STUDIES; DATABASES, FACTUAL; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REPORTING; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 78650926141     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-6     Document Type: Article

References (24)

1. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999, 50(10):1303-1308.
2. Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther 2002, 24(10):1668-1676. 10.1016/S0149-2918(02)80070-4, 12462295.
3. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994, 31(4):281-294. 10.1016/0165-0327(94)90104-X, 7989643.
4. Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord 2002, 71(1-3):131-139. 10.1016/S0165-0327(01)00394-9, 12167509.
5. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002, 159(6):1005-1010. 10.1176/appi.ajp.159.6.1005, 12042190.
6. Guo JJ, Keck PE, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry 2006, 67(7):1055-1061. 10.4088/JCP.v67n0707, 16889448.
7. APA Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159(4 Suppl):1-50. APA.
8. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003, 17(2):149-173. discussion 147, 10.1177/0269881103017002003, 12870562.
9. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Moller HJ, . Disorders WTFoTGfB The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry 2003, 4(1):5-13. 10.3109/15622970309167904, 12582971, Disorders WTFoTGfB.
10. Yatham LN. Atypical antipsychotics for bipolar disorder. Psychiatr Clin North Am 2005, 28(2):325-347. 10.1016/j.psc.2005.01.001, 15826735.
11. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005, 66(7):870-886. 10.4088/JCP.v66n0710, 16013903.
12. Guo JJ, Keck PE, Li H, Jang R, Kelton CM. Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population. Value Health 2008, 11(3):416-423. 10.1111/j.1524-4733.2007.00287.x, 18179673.
13. Kim E, Maclean R, Ammerman D, Jing Y, Pikalov A, You M, Van-Tran Q, L'Italien G. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis. Clin Ther 2009, 31(4):836-848. 10.1016/j.clinthera.2009.04.022, 19446157.
14. Jing Y, Kim E, You M, Pikalov A, Tran QV. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. J Med Econom 2009, 12(2):104-113. 10.3111/13696990903044092, 19527195.
15. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006, 98(3):253-259. 10.1111/j.1742-7843.2006.pto_293.x, 1790968, 16611199.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45(6):613-619. 10.1016/0895-4356(92)90133-8, 1607900.
17. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999, 20:125-144. 10.1146/annurev.publhealth.20.1.125, 10352853.
18. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 2005, 24(3):465-488. 10.1016/j.jhealeco.2004.09.011, 15811539.
19. Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. The association between treatment adherence and antipsychotic dose among individuals with bipolar disorder. Int Clin Psychopharmacol 2008, 23(6):305-316. 10.1097/YIC.0b013e32830b0f88, 18854718.
20. Citrome L, Reist C, Palmer L, Montejano L, Lenhart G, Cuffel B, Harnett J, Sanders KN. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res 2009, 108(1-3):238-244. 10.1016/j.schres.2008.11.017, 19106035.
21. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry 2006, 67(2):222-232. 10.4088/JCP.v67n0208, 16566617.
22. Wang Z, Salmon JW, Walton SM. Cost-effectiveness analysis and the formulary decision-making process. J Manag Care Pharm 2004, 10(1):48-59.
23. Pearl J. Causality: Models, Reasoning and Inference 2009, Cambridge University Press, 2.
24. Heckman. Econometric causality. National Bureau of Economic Research Working paper 13934 2008,